13 Stock Overview
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 13 from our risk checks.
My Notes
Capture your thoughts, links and company narrative
HUTCHMED (China) Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£22.40 |
| 52 Week High | UK£35.90 |
| 52 Week Low | UK£19.00 |
| Beta | 0.74 |
| 1 Month Change | -17.95% |
| 3 Month Change | -19.13% |
| 1 Year Change | -14.99% |
| 3 Year Change | -60.42% |
| 5 Year Change | n/a |
| Change since IPO | -63.16% |
Recent News & Updates
Recent updates
Shareholder Returns
| 13 | HK Pharmaceuticals | HK Market | |
|---|---|---|---|
| 7D | -3.7% | 2.0% | 2.3% |
| 1Y | -15.0% | -2.6% | 22.4% |
Return vs Industry: 13 underperformed the Hong Kong Pharmaceuticals industry which returned -3.8% over the past year.
Return vs Market: 13 underperformed the Hong Kong Market which returned 21.1% over the past year.
Price Volatility
| 13 volatility | |
|---|---|
| 13 Average Weekly Movement | 7.0% |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in HK Market | 18.5% |
| 10% least volatile stocks in HK Market | 4.0% |
Stable Share Price: 13 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 13's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 1,970 | Wei-Guo Su | www.hutch-med.com |
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases.
HUTCHMED (China) Limited Fundamentals Summary
| 13 fundamental statistics | |
|---|---|
| Market cap | HK$20.14b |
| Earnings (TTM) | -HK$326.00m |
| Revenue (TTM) | HK$4.74b |
4.2x
P/S Ratio-61.8x
P/E RatioIs 13 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 13 income statement (TTM) | |
|---|---|
| Revenue | US$610.81m |
| Cost of Revenue | US$658.26m |
| Gross Profit | -US$47.45m |
| Other Expenses | -US$5.48m |
| Earnings | -US$41.97m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.049 |
| Gross Margin | -7.77% |
| Net Profit Margin | -6.87% |
| Debt/Equity Ratio | 10.9% |
How did 13 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 04:53 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
HUTCHMED (China) Limited is covered by 46 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jiangqiao Tong | BOCI Research Ltd. |
| Linda Lu | BOCI Research Ltd. |
| Alec Stranahan | BofA Global Research |